Fig. 4. Phase II pancreatic cancer clinical trial candidates that failed to show statistically significant improvements in MoS or failed at phase II for other reasons as either single agents or in combination with gemcitabine (1): vandetanib (23), sorafenib (24), erlotinib (25), dasatinib (26), saracatinib (27), imatinib (28) vismodegib (29), dactolisib (30), everolimus (31), PX-12 (32), veliparib (33), trametinib (34) and selumetinib (35). Note that erlotinib (25) in combination with gemcitabine (1) was approved for locally advanced, unresectable or metastatic PC in 2005.60.